PlumBot: Bot: Creating new article from JSON

2026-03-15T04:30:07Z

Bot: Creating new article from JSON

New page

💊 '''Specialty drug''' refers to a class of high-cost, complex pharmaceutical products — including biologics, gene therapies, and targeted small-molecule treatments — that represent one of the fastest-growing cost drivers in [[Definition:Health insurance | health insurance]] and [[Definition:Pharmacy benefit management | pharmacy benefit management]] worldwide. For insurers writing medical, pharmacy, or [[Definition:Stop-loss insurance | stop-loss]] coverage, specialty drugs present a distinct actuarial and underwriting challenge because a single patient's annual treatment cost can reach hundreds of thousands of dollars, creating the potential for outsized [[Definition:Claims | claims]] that distort [[Definition:Loss ratio | loss ratios]] for entire risk pools. The category has no single universal definition, but industry convention and formulary classifications generally identify specialty drugs by characteristics such as high unit cost, complex administration (infusion, injection, or special handling), requirements for patient monitoring, and limited distribution channels.

⚙️ From an insurance operations standpoint, managing specialty drug exposure involves a layered set of controls. [[Definition:Pharmacy benefit manager (PBM) | Pharmacy benefit managers]] implement prior authorization protocols, step therapy requirements, and formulary tiering to steer utilization toward the most cost-effective options. [[Definition:Health insurance | Health insurers]] and [[Definition:Self-insured retention (SIR) | self-funded employers]] increasingly carve out specialty pharmacy benefits to specialized networks that negotiate pricing directly with manufacturers. [[Definition:Reinsurance | Reinsurers]] offering [[Definition:Stop-loss insurance | stop-loss]] and [[Definition:Excess of loss reinsurance | excess of loss]] coverage for group health plans must model specialty drug trend separately from traditional pharmacy costs because utilization patterns and price trajectories follow fundamentally different curves. The emergence of cell and gene therapies — some carrying one-time price tags exceeding one million dollars — has prompted the development of outcomes-based contracts and installment payment models that spread the financial impact over multiple policy periods, a relatively novel concept for both insurers and manufacturers.

📊 The broader strategic impact on the insurance industry is substantial. Specialty drugs now account for a disproportionate share of total pharmacy spend in mature health insurance markets, particularly in the United States, where they have reshaped how [[Definition:Actuary | actuaries]] project medical trend and how [[Definition:Underwriter | underwriters]] price group and individual health plans. In markets with national health systems — such as the United Kingdom's NHS or Japan's universal coverage framework — specialty drug costs increasingly flow through supplementary private insurance products or government reinsurance mechanisms. For [[Definition:Life insurance | life insurers]] and [[Definition:Disability insurance | disability carriers]], the availability of specialty drugs that transform previously fatal or debilitating conditions into manageable chronic illnesses has implications for mortality and morbidity assumptions, necessitating ongoing revisions to pricing models and [[Definition:Reserves | reserve]] methodologies.

'''Related concepts:'''
{{Div col|colwidth=20em}}
* [[Definition:Health insurance]]
* [[Definition:Pharmacy benefit manager (PBM)]]
* [[Definition:Stop-loss insurance]]
* [[Definition:Loss ratio]]
* [[Definition:Medical trend]]
* [[Definition:Reinsurance]]
{{Div col end}}

Definition:Specialty drug - Revision history

PlumBot: Bot: Creating new article from JSON